Abstract
Agitation is commonly seen in acute schizophrenic patients and core symptoms include a wide range of symptom. It requires rapid and effective treatment approaches in order to protect patient and caregiver from potential injury. Clinicians decision of pharmacological treatment should be individualized to the needs and circumstances of the patient. Benzodiazepines, typical antipsychotics, and combinations of typical antipsychotics and benzodiazepines have been widely used as treatment options. Atypical antipsychotics have clear advantages over the typical drugs as they generally show a much better safety and tolerability profile, particularly to EPS and related side effects, however clinical perception regarding efficacy in treating acutely agitated psychotic patient is controversial. New intramuscular atypical antipsychotic formulations offer evidence of being at least as effective as typical antipsychotics in controlling agitation. Therefore, they should be considered as first line therapy in agitated schizophrenic patients.
Keywords: atypical antipsychotics, intramuscular, schizophrenia, agitation
Current Pharmaceutical Design
Title: Pharmacological Management of Acutely Agitated Schizophrenic Patients
Volume: 11 Issue: 19
Author(s): L. San, B. Arranz and R. Escobar
Affiliation:
Keywords: atypical antipsychotics, intramuscular, schizophrenia, agitation
Abstract: Agitation is commonly seen in acute schizophrenic patients and core symptoms include a wide range of symptom. It requires rapid and effective treatment approaches in order to protect patient and caregiver from potential injury. Clinicians decision of pharmacological treatment should be individualized to the needs and circumstances of the patient. Benzodiazepines, typical antipsychotics, and combinations of typical antipsychotics and benzodiazepines have been widely used as treatment options. Atypical antipsychotics have clear advantages over the typical drugs as they generally show a much better safety and tolerability profile, particularly to EPS and related side effects, however clinical perception regarding efficacy in treating acutely agitated psychotic patient is controversial. New intramuscular atypical antipsychotic formulations offer evidence of being at least as effective as typical antipsychotics in controlling agitation. Therefore, they should be considered as first line therapy in agitated schizophrenic patients.
Export Options
About this article
Cite this article as:
San L., Arranz B. and Escobar R., Pharmacological Management of Acutely Agitated Schizophrenic Patients, Current Pharmaceutical Design 2005; 11 (19) . https://dx.doi.org/10.2174/1381612054367472
DOI https://dx.doi.org/10.2174/1381612054367472 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chronic Inflammation in the Pancreas and Salivary Glands - Lessons from Similarities and Differences in Pathophysiology and Treatment Modalities
Current Pharmaceutical Design The Role of Progenitor Cells in Osteoarthritis Development and Progression
Current Stem Cell Research & Therapy Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple Myeloma
Current Cancer Therapy Reviews Innovations to Control the Environment for Persons with Movement Disorders: Support in Home Care
Recent Patents on Biomedical Engineering (Discontinued) Strategies of Engineering Nanoparticles for Treating Neurodegenerative Disorders
Current Drug Metabolism Genetic Variation of Chromosome 1q42: Etiologic Mechanism of Congenital Disorders of Neuronal Migration and Synaptogenesis
Current Psychiatry Reviews Withdrawal Notice: A Panoramic View on the Phytochemical, Nutritional and Therapeutic value of Ziziphus mauritiana Lam.: A Comprehensive Review
Mini-Reviews in Medicinal Chemistry Somatic Treatments Excluding Psychopharmacology in Obsessive- Compulsive Disorder: A Review.
Reviews on Recent Clinical Trials In Silico Approaches Towards the Understanding of the Structure- Function Relationships in Metabotropic Glutamate Receptors (mGluRs) and other Family C GPRCs
Current Pharmaceutical Design Passive Smoking, Asthma and Allergy in Children
Inflammation & Allergy - Drug Targets (Discontinued) Insect Peptides – Perspectives in Human Diseases Treatment
Current Medicinal Chemistry A Review of Lysergic Acid Diethylamide (LSD) in the Treatment of Addictions: Historical Perspectives and Future Prospects
Current Drug Abuse Reviews The Proteolytic Activation of Angiogenic and Lymphangiogenic Growth Factors in Cancer – Its Potential Relevance for Therapeutics and Diagnostics
Current Medicinal Chemistry The Development and Progression of Atherosclerosis: Evidence supporting a Role for Endoplasmic Reticulum (ER) Stress Signaling
Cardiovascular & Hematological Disorders-Drug Targets Kinase Inhibitors as Potential Therapeutics for Acute and Chronic Neurodegenerative Conditions
Current Pharmaceutical Design Magnetic Resonance Spectroscopy Biomarkers in Term Perinatal Asphyxial Encephalopathy: From Neuropathological Correlates to Future Clinical Applications
Current Pediatric Reviews Metabolite Quantification in Tumours by Magnetic Resonance Spectroscopy: Objectives, Results and Perspectives
Current Medical Imaging Molecular Modeling of Human Hepatocyte PKA (cAMP-Dependent Protein Kinase Type-II) and Its Structure Analysis
Protein & Peptide Letters Molecular Biology, Pharmacology and Functional Role of the Plasma Membrane Dopamine Transporter
CNS & Neurological Disorders - Drug Targets Linking New Paradigms in Protein Chemistry to Reversible Membrane-Protein Interactions
Current Protein & Peptide Science